Highlight Capital

Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.

Silicon Innovation is a technology company based in Chengdu, China, specializing in interconnect chip solutions for the enterprise sector. Established in December 2019, the company focuses on the development of high-end analog and digital-analog hybrid chips, which cater to various applications including clocks, interfaces, and power management. Silicon Innovation's products support critical industries such as data centers, 5G communications, artificial intelligence, autonomous driving, intelligent monitoring, new energy vehicles, and the Internet of Things. By providing advanced chip solutions, the company enables businesses to enhance their systems and products across multiple sectors.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Thousand Oaks Biopharmaceuticals, Inc., established in 2017 and located in Haimen, China, specializes in contract development and manufacturing services tailored for the biotechnology sector. The company focuses on developing biopharmaceutical technologies aimed at producing protein and vaccine compounds. It offers integrated control solutions that enhance production processes by optimizing protein expression and reducing production scale. This enables biopharmaceutical companies to access personalized, chemically-defined cell culture media, formula production, technical support, and ancillary services. By providing these comprehensive services, Thousand Oaks Biopharmaceuticals aims to facilitate the creation of accessible and affordable biologics to meet global healthcare needs.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based company specializing in the research and pre-clinical development of therapies for immunology-related conditions. Founded in 2019, it focuses on addressing unmet medical needs globally through a unique approach termed "Borderless Innovation." The company is developing a pipeline of drug candidates, including IMG-020, a protein drug designed to target IL-17A, utilizing advanced technologies that enhance potency and extend the drug's half-life. Inmagene aims to create a new generation of therapeutics characterized by improved pharmacokinetics, pharmacodynamics, and safety profiles, which may lead to better efficacy and dosing convenience. With additional offices in Hangzhou and Beijing, Inmagene is committed to leveraging innovative resources and processes to facilitate drug development across borders, thereby enhancing the potential for positive patient outcomes worldwide.

Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform, providing first-in-class new molecules consistently and efficiently. Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China.

Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

Xingyun Group specializes in reconstructing the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company utilizes whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine focuses on integrating industrial resources to reduce costs and improve efficiency through data-driven insights. Xingyun Group assists overseas consumer brands in entering the Chinese market while also facilitating the global expansion of Chinese brands. The company boasts nearly 160 warehouses located in 72 countries and one region, serving over 350,000 retailers both online and offline in China. Its platform encompasses a diverse range of products, including maternal and child supplies, beauty care, healthcare, and clothing, enabling retailers to procure goods quickly and cost-effectively.

Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

Genetron Health is a prominent oncology company based in China, specializing in precision medicine and cancer molecular profiling. The firm focuses on developing health management products that encompass all aspects of cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. By leveraging advanced technologies in molecular biology and data science, Genetron Health effectively applies genomic data to support medical professionals and researchers. The company offers reliable molecular clinical services and professional cancer genetic risk assessments to patients, including those at high risk and healthy individuals. Over three years, Genetron Health has established global genomics sequencing and bioinformatics platforms, alongside R&D centers in North Carolina and Beijing, and clinical laboratories across several Chinese cities. Looking ahead, Genetron Health plans to expand its sales network throughout China, aiming to provide comprehensive services to both Chinese and global cancer patients, supported by its expertise in cancer genomics and clinical translation.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Julikang is a third-party medical device disinfection service provider focused on the healthcare industry in China. The company offers disinfection services to numerous hospitals, utilizing automated cleaning devices to ensure thorough sanitation of items and areas. By interfacing with hospital information systems, Julikang implements sterile item traceability management software, which enhances the management of sterile articles. This integration allows real-time access to physical parameter information of medical devices, ensuring efficient traceability and compliance with hygiene standards. Through its services, Julikang aims to deliver professional quality sterilization and disinfection solutions to healthcare enterprises.

Angstrom STEM is a brand of Anglia Education Group, integrating the resources and achievements of science and technology education of Shanghai Jiaotong University, and introducing the technology experience model of the United States and Canada, innovatively opening up STEM entertainment and education, integrating scientific experiments, model construction, mechanical energy, robot construction With programming, 3D printing, mathematics, etc., and focusing on the application and innovation of the latest science and technology, we have established a complete scientific STEM curriculum system to promote the quality education of domestic children and build a leading high-end STEM education brand in China.

Boholo, founded in 2011 and based in Shanghai, China, offers a digital medical management solution that integrates various advanced technologies. Its platform includes services such as clinical case management, three-dimensional surgical modeling and planning, and a multimedia case database. By utilizing artificial intelligence and machine vision, Boholo's medical imaging tools generate precise 3D anatomical models that assist medical professionals in planning surgical procedures, thereby increasing the likelihood of successful outcomes. The company also provides a comprehensive service platform that facilitates communication among specialists worldwide, enhancing their ability to deliver quality care.

BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.

GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Predicine Huidu Medical Technology Co., Ltd. is located in Fengxian, China, and specializes in the research and development of innovative technologies in the healthcare sector. The company focuses on gene detection methods and bioinformatics algorithms specifically designed for cancer diagnosis and monitoring. By creating a clinical application platform, Predicine Huidu Medical Technology connects patients with healthcare companies, facilitating advancements in tumor diagnosis and treatment. Through its technological offerings, the company aims to enhance the accuracy and effectiveness of cancer care.

Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its services encompass a range of clinical inspection instruments, including chemiluminescence and biochemical reagents, as well as technical support, management, and certification. Additionally, Chemclin operates independent medical laboratories and is focused on introducing innovative diagnostic products and services to the Chinese market.

Chowsing Live is an online retailer based in Shanghai, China, specializing in pet products and accessories. The company offers a range of items, including pet jumbo wipes, cat collars with bells, and flushable cat litters. Chowsing Live focuses on promoting design and creativity in its product development, aiming to address the genuine needs of pets and their owners. By providing innovative solutions, the company strives to foster a natural and harmonious lifestyle for both pets and pet-raising families.

GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Sansure Biotech Inc. is a biotechnology company based in Changsha, Hunan Province, specializing in molecular diagnostics and genetic testing. Established in 2008, the company develops and sells a range of products, including nucleic acid extraction kits and real-time PCR diagnostic and research kits, as well as fluorescence systems. Its offerings include diagnostic kits for various diseases such as COVID-19, viral hepatitis, AIDS, cancer-related biomarkers, and respiratory tract infections, among others. Sansure Biotech serves hospitals and laboratories both in China and internationally, providing essential medical devices and laboratory equipment designed for accurate diagnoses and research in the field of molecular biology.

EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

General Healthy specializes in pharmaceutical logistics automation and mobile medical solutions. Based in Shanghai, the company offers products and services designed for the intelligent management of medicines, catering to both medical services and the pharmaceutical circulation industries. Through its innovative approach, General Healthy aims to enhance the efficiency and effectiveness of medicine management, addressing the needs of healthcare providers and pharmaceutical distributors.

Rundong Pharmaceutical R&D is a contract research organization (CRO) that focuses on clinical research outsourcing for pharmaceutical and biotechnology companies. It offers a comprehensive range of services, including clinical operations, medical data management, biostatistics, and medical project management. As a key player in the industry, Rundong is the main initiator and promoter of the China CRO Alliance, highlighting its leadership role in the field. The company has also achieved the distinction of being the first CRO in China to receive ISO 9001:2008 quality management system certification, demonstrating its commitment to high-quality standards in clinical research. Through its professional services, Rundong aims to support various companies in the pharmaceutical and biotech sectors in advancing their medical research initiatives.

Tellyes Scientific Inc. specializes in the manufacture and marketing of healthcare equipment aimed at the medical education and training sectors. Founded in 2001 and headquartered in Tianjin, China, the company offers a diverse range of products, including patient simulators, surgical simulators, ultrasound and imaging simulators, task trainers, and dental simulators. Tellyes Scientific also provides solutions for planning and managing training centers and engages in tele-simulation. The company's innovative approach encompasses research and development in various fields, including training software and traditional Chinese medicine training systems. With a portfolio of over a thousand types of medical virtual teaching products, Tellyes Scientific serves a global market through a network of distributors across Asia, Africa, the Middle East, Europe, North America, and Latin America.

Kontour Medical is a company based in Xi'an, China, specializing in the research and development, production, and sale of medical devices for various surgical fields, including neurosurgery, cardiovascular surgery, craniofacial surgery, and stomatology. Founded in 2005, the company offers a diverse range of products, including titanium mesh and PEEK cranial fixation systems for neurosurgery, sternum and rib fixation systems for thoracic surgery, and interbody fusion cages for neurospine applications. Additionally, Kontour Medical provides oral implant systems featuring titanium and titanium alloy dental implants, along with other surgical products such as hernia repair patches and lamina plates. Through its commitment to innovation and quality, Kontour Medical aims to enhance surgical outcomes and patient care in the medical device industry.

Jikai Gene Chemical Technology Co., Ltd. is headquartered in Shanghai Zhangjiang Hi-Tech Park, a national high-tech park. It is a high-tech enterprise integrating genetic technology service, research and development, technology transformation, product development, production and sales. .